Neurochemical Effects of Omega-3 Fatty Acids in Adolescents at Risk for Mania (R34)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00917501
Recruitment Status : Completed
First Posted : June 10, 2009
Results First Posted : June 9, 2016
Last Update Posted : June 9, 2016
National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Robert McNamara, University of Cincinnati

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition: Mania
Interventions: Drug: OMega 3
Drug: Placebo

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Placebo Olive oil - 3 capsules/day
Omega-3 Fish oil - 3 capsules/day

Participant Flow:   Overall Study
    Placebo   Omega-3
STARTED   29   26 
COMPLETED   21   21 
Lost to Follow-up                4                1 
Withdrawal by Subject                3                1 
Lack of Efficacy                1                2 
trouble swollowing capsules                0                1 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Placebo Olive oil - 3 capsules/day
Omega-3 Fish oil - 3 capsules/day
Total Total of all reporting groups

Baseline Measures
   Placebo   Omega-3   Total 
Overall Participants Analyzed 
[Units: Participants]
 29   26   55 
[Units: Years]
Mean (Standard Deviation)
 13.4  (3.3)   13  (4.5)   13.2  (3.9) 
[Units: Participants]
Female   24   21   45 
Male   5   5   10 
Region of Enrollment 
[Units: Participants]
United States   29   26   55 

  Outcome Measures

1.  Primary:   Change From Baseline in Depression Symptom Severity at 12 Weeks   [ Time Frame: Baseline and 12 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Dr. Robert McNamara
Organization: University of Cincinnati
phone: 513-558-5601

Responsible Party: Robert McNamara, University of Cincinnati Identifier: NCT00917501     History of Changes
Other Study ID Numbers: Del/McNa OMega 3
First Submitted: June 8, 2009
First Posted: June 10, 2009
Results First Submitted: October 26, 2015
Results First Posted: June 9, 2016
Last Update Posted: June 9, 2016